Breast Cancer – Pipeline Review, H1 2012

Breast Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Breast Cancer - Pipeline Review, H1 2012', provides an overview of the Breast Cancer therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. 'Breast Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Breast Cancer.
• A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Breast Cancer.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Breast Cancer therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Breast Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Breast Cancer
Breast Cancer Therapeutics under Development by Companies
Breast Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Breast Cancer Therapeutics – Products under Development by Companies
Breast Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Breast Cancer Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Celsion Corporation
Abbott Laboratories
Biogen Idec Inc.
Amgen Inc.
Sanofi-Aventis
Adherex Technologies Inc.
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Seattle Genetics, Inc.
Tekmira Pharmaceuticals Corp.
Genentech, Inc.
Nektar Therapeutics
Biotec Pharmacon ASA
Bavarian Nordic A/S
Daiichi Sankyo Company, Ltd
Immunovative Therapies, Ltd.
Oncozyme Pharma Inc.
BerGenBio AS
CytomX, LLC.
Breast Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Halaven - Drug Profile
SNDX 275 - Drug Profile
Nexavar - Drug Profile
RG3502 - Drug Profile
Pertuzumab - Drug Profile
Decapeptyl - Drug Profile
NKTR-102 - Drug Profile
Tavocept - Drug Profile
Avastin - Drug Profile
Faslodex - Drug Profile
Afinitor - Drug Profile
BSI-201 - Drug Profile
IMC-1121B - Drug Profile
NeuVax - Drug Profile
OPT-822/OPT-821 - Drug Profile
Tykerb - Drug Profile
SU011248 + Paclitaxel - Drug Profile
Imatinib + Vinorelbine - Drug Profile
Afinitor + Exemestane - Drug Profile
Everolimus + Trastuzumab + Vinorelbine - Drug Profile
Docetaxel + Doxorubicin + Cyclophosphamide - Drug Profile
Ixempra + Cyclophosphamide + Doxorubicin - Drug Profile
Vinflunine + Capecitabine - Drug Profile
Doxorubicine + Cyclophosphamide + Herceptin + Taxotere - Drug Profile
Afatinib + Vinorelbine - Drug Profile
Afatinib - Drug Profile
Tykerb + Paclitaxel - Drug Profile
BSI-201 + Gemcitabine + Carboplatin - Drug Profile
Lapatinib + Trastuzumab - Drug Profile
Paclitaxel + Trastuzumab + GW572016 - Drug Profile
Tykerb + Votrient - Drug Profile
Avastin + Xeloda - Drug Profile
Letrozole + Zoledronic Acid - Drug Profile
Avastin + Herceptin + Docetaxel - Drug Profile
Herceptin + Avastin - Drug Profile
Pertuzumab + Herceptin + Docetaxel - Drug Profile
Pertuzumab + Herceptin - Drug Profile
Avastin + Taxane - Drug Profile
Herceptin + Docetaxel + 5-fluorouracil + Epirubicin + Cyclophosphamide - Drug Profile
Zometa + Femara - Drug Profile
Myocet + Taxol + Herceptin - Drug Profile
Trastuzumab-DM1 + Pertuzumab - Drug Profile
Paclitaxel/Docetaxel + Lapatinib - Drug Profile
Lapatinib + Trastuzumab + Letrozole - Drug Profile
IMC-1121B + Docetaxel - Drug Profile
Lapatinib + Trastuzumab + Anastrozole - Drug Profile
Lapatinib + Trastuzumab + Exemestane - Drug Profile
Aromasin + Entinostat - Drug Profile
RAD001 + Trastuzumab + Paclitaxel - Drug Profile
Nexavar + Capecitabine - Drug Profile
CT-P06 - Drug Profile
Herceptin - Drug Profile
Herceptin - Drug Profile
Avastin + Standard Chemotherapy - Drug Profile
Breast Cancer Therapeutics – Drug Profile Updates
Breast Cancer Therapeutics – Discontinued Products
Breast Cancer Therapeutics - Dormant Products
Breast Cancer – Product Development Milestones
Featured News & Press Releases
Jan 11, 2012: Cancer Research UK Launches Outpatients Phase II Clinical Trial Of Breast And Ovarian Cancer Drug
Jan 03, 2012: Eisai Receives J-Code From Centers For Medicare And Medicaid Services For Halaven Injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Breast Cancer, H1 2012
Products under Development for Breast Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
Boehringer Ingelheim GmbH, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Celsion Corporation, H1 2012
Abbott Laboratories, H1 2012
Biogen Idec Inc., H1 2012
Amgen Inc., H1 2012
Sanofi-Aventis, H1 2012
Adherex Technologies Inc., H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
Viralytics Ltd., H1 2012
GlaxoSmithKline plc, H1 2012
Seattle Genetics, Inc., H1 2012
Tekmira Pharmaceuticals Corp., H1 2012
Genentech, Inc., H1 2012
Nektar Therapeutics, H1 2012
Biotec Pharmacon ASA, H1 2012
Bavarian Nordic A/S, H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Merck & Co., Inc., H1 2012
A&G Pharmaceutical, Inc., H1 2012
Oxford BioMedica plc, H1 2012
Infinity Pharmaceuticals, Inc., H1 2012
Generex Biotechnology Corporation, H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
Ipsen S.A., H1 2012
MediGene AG, H1 2012
Celltrion, Inc., H1 2012
Bio-Path Holdings, Inc., H1 2012
Epeius Biotechnologies Corporation, H1 2012
Immunovative Therapies, Ltd., H1 2012
Oncozyme Pharma Inc., H1 2012
BerGenBio AS, H1 2012
CytomX, LLC., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Breast Cancer Therapeutics – Drug Profile Updates
Breast Cancer Therapeutics – Discontinued Products
Breast Cancer Therapeutics – Dormant Products

LIST OF FIGURES

Number of Products under Development for Breast Cancer, H1 2012
Products under Development for Breast Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012 Skip to top